Posted by Michael Wonder on 16 Jun 2020
FDA approves Lyumjev (insulin lispro-aabc injection), Lilly's new rapid-acting insulin
15 June 2020 - The U.S. FDA has approved Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company's new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Lyumjev is a novel formulation of insulin lispro, developed to speed the absorption of insulin into the blood stream and reduce A1C levels.
As a rapid-acting mealtime insulin, Lyumjev controls high blood sugar levels after meals in adults with diabetes, similar to how natural insulin works after meals in people without diabetes.
